Revolutionizing Clinical Trials: How AI Chatbots Boost Patient Experience & Recruitment by 50%


Abhishek Founder & CFO cisin.com
In the world of custom software development, our currency is not just in code, but in the commitment to craft solutions that transcend expectations. We believe that financial success is not measured solely in profits, but in the value we bring to our clients through innovation, reliability, and a relentless pursuit of excellence.


Contact us anytime to know moreAbhishek P., Founder & CFO CISIN

 

Revolutionizing Clinical Trials: AI Chatbots Boost Recruitment!

KPCB's Mary Meeker's Internet Trends 2017 reports said that the amount of clinical trials has grown by over 10 times between 2006 and 2016 and also the range of publicly available clinical trial results has increased from 1.9K to 25.4K between 2009 and 2016. There is also a marked difference in the way generations get into the ever-growing health data. By way of instance, millennials possess wearables, go on the web to find a physician and select providers based on online reviews in a significantly higher speed than Gen X-ers and baby boomers. The newer productions' behaviors with respect to devices, voice ports, and messaging platforms are also becoming profoundly different.

Businesses conducting clinical trials have found it more difficult to seek out and enroll patients, particularly in the USA and other developed countries since medication get approved first in such countries resulting in reduced wait times for patients and not having to resort to experimental drugs. Furthermore, physicians have a tendency to have limited time with patients and as a way to spell out the benefits and risks connected with an experimental medication limiting the opportunity for possible participants from getting their questions answered.


AI/ML programs across the healthcare industry -- NLP chatbots considerably improves the convenience of the patient.

AI/ML programs across the healthcare industry -- NLP chatbots considerably improves the convenience of the patient.

 

We feel that an AI/NLP-based, well trained and trainable text along with voice-based conversational chatbot will tackle those struggles. Support over multiple platforms like the desktop computer or cellular phone, messaging programs like Facebook Messenger, WeChat and voice assistants such as Amazon Echo and Google Home would enable vast coverage and friction-less and omnipresent access for patients. Recently several HIPAA compliant messaging platforms and software have arisen, which make regulatory compliance of healthcare data. Clinical trial websites can mandate the use of one or more such programs, for instance, and in the event the chatbot can work over these apps, while integrating easily with additional electronic health records (EMR) systems through webhooks such as REST APIs (Representational State Transfer Application Programming Interfaces), the resulting solution becomes an extremely potent and also an effective communication tool.

The patients and potential patients would like to find trial questions answered quickly before recruitment, be conscious of their options, get questions answered including the Informed Consent Form (ICF) within the course of the trial and have the capability to get into these from multiple programs seamlessly and get reminders for appointments and tests. Using push notifications, the CRO/clinical trial site might send reminders to the patients such as medication program. Furthermore, patients may upload compliance advice such as verifying medicine intake, what they ate during relevant meal intervals and documenting any additional relevant information. By offering universal and easy access, patients are more likely to give compliance information, which would create the clinical trial outcome and diagnosis more accurate.

The clinical trial ecosystem consists of the pharmaceutical business, contract research organizations (CROs), trial sites and a potential pool of patients. The pharmaceutical companies are keen on increasing recruitment and policy of trials, including the expanding cost of conducting trials (especially in the US), instructing investigators and site staff regarding the research/experimental drug and improving patient experiences (such as healthy volunteer trials). The CROs are searching to increase recruiting efficacy and reach, decrease the expense to do trials and also improve communication with site staff. The investigators and site coordinators wish to take care of the problem of investigators getting just limited time with patients, increase recruitment effectiveness, remind patients about upcoming appointments and make trial advice more accessible for patients and track compliance. An AI-based conversational interface provides a specific remedy.